Internet Archive Scholar

Safety, Tolerability, Pharmacokinetics and Antitumor Activity of Ganitumab, an Investigational Fully Human Monoclonal Antibody to Insulin-like Growth Factor Type 1 Receptor, Combined with Gemcitabine as First-line Therapy in Patients with Metastatic Pancreatic Cancer: A Phase 1b Study

Takuji Okusaka, Masafumi Ikeda, Akira Fukutomi, Yoshikazu Kobayashi, Kazuhiro Shibayama, Takatoshi Takubo, Jennifer Gansert
2014 Japanese Journal of Clinical Oncology  

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (160.5 kB)
https://web.archive.org/web/20190302194143/http://pdfs.semanticscholar.org/a111/00924e1acbfbac59b15b560ae322cdece381.pdf

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL. The file type is application/pdf.

Objective: Previous Phase 1 studies have shown the acceptable safety profile of ganitumaba fully human monoclonal antibody to insulin-like growth factor Type 1 receptor-in patients with advanced solid tumors. However, ganitumab 20 mg/kg in combination with gemcitabine had not been administered to patients with metastatic pancreatic cancer. To evaluate the safety, tolerability, pharmacokinetics and antitumor activity of ganitumab 20 mg/kg combined with gemcitabine 1000 mg/m 2 as first-line
more » ... y in patients with metastatic pancreatic cancer, we conducted a Phase 1b study. Methods: Eligible patients were adults with previously untreated metastatic adenocarcinoma of the pancreas. Patients received gemcitabine 1000 mg/m 2 on Days 1, 8 and 15 plus ganitumab 20 mg/kg on Days 1 and 15 of each 28-day cycle. Gemcitabine was administered intravenously over 30 -60 min. Ganitumab was administered intravenously over 60 min after completing gemcitabine infusion. Results: Six patients were enrolled and received the study treatment. All patients had thrombocytopenia and leukopenia. Other most common adverse events were neutropenia and nausea. One patient had a dose-limiting toxicity defined as Grade 3 neutropenia with fever. Exposure to ganitumab 20 mg/kg was not affected by the administration of gemcitabine. No apparent pharmacokinetic drug -drug interaction was observed. No anti-ganitumab antibodies were detected. Five patients had a measurable tumor region at baseline. Of these, four patients had a best response of stable disease. Conclusions: Ganitumab 20 mg/kg combined with gemcitabine 1000 mg/m 2 was tolerable and showed an acceptable safety profile in patients with untreated metastatic pancreatic cancer.
doi:10.1093/jjco/hyu034 pmid:24782485 fatcat:3vt5rejwxreaza4jx2tyqmphqu
Citation

Takuji Okusaka, Masafumi Ikeda, Akira Fukutomi, Yoshikazu Kobayashi, Kazuhiro Shibayama, Takatoshi Takubo, Jennifer Gansert. "Safety, Tolerability, Pharmacokinetics and Antitumor Activity of Ganitumab, an Investigational Fully Human Monoclonal Antibody to Insulin-like Growth Factor Type 1 Receptor, Combined with Gemcitabine as First-line Therapy in Patients with Metastatic Pancreatic Cancer: A Phase 1b Study." Japanese Journal of Clinical Oncology 44.5 (2014) 442-447